In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6324-6327

  Van Ingen, Jakko ^a,b   Totten, Sarah E ^a   Helstrom, Niels K ^a   Heifets, Leonid B ^a   Boeree, Martin J ^b   Daley, Charles L ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CLOFAZIMINE;

ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM SIMIAE; PRIORITY JOURNAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; CLOFAZIMINE; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; NONTUBERCULOUS MYCOBACTERIA;

EID: 84869232612     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01505-12     Document Type: Article

References (23)

1. Adékambi T, Berger P, Raoult D, Drancourt M. 2006. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int. J. Syst. Evol. Microbiol. 56:133-143.
2. Ben Salah I, Adékambi T, Raoult D, Drancourt M. 2008. rpoB sequence-based identification of Mycobacterium avium complex species. Microbiology 154:3715-3723.
3. Bopape MC, et al. 2004. Antimicrobial activity of clofazimine is not dependent on mycobacterial C-type phospholipases. J. Antimicrob. Chemother. 53:971-974.
4. Cholo MC, et al. 2006. Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 57:79-84.
5. Clinical and Laboratory Standards Institute. 2011. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes. Approved standard. CLSI document M24-A2. CLSI, Wayne, PA.
6. Field SK, Cowie RL. 2003. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 124:1482-1486.
7. Gangadharam PR, Perumal VK, Podapati NR, Kesavalu L, Iseman MD. 1988. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob. Agents Chemother. 32:1400-1403.
8. Griffith DE, et al. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
9. Jarand J, et al. 2011. Clinical and microbiological outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin. Infect. Dis. 52:565-571.
10. Jeon K, et al. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am. J. Respir. Crit. Care Med. 180:896-902.
11. Ji B, Lounis N, Truffot-Pernot C, Grosset J. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob. Agents Chemother. 38:2521-2529.
12. Leao SC, Tortoli E, Euzéby JP, Garcia MJ. 2011. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int. J. Syst. Evol. Microbiol. 61:2311-2313.
13. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
14. Reddy VM, O'Sullivan JF, Gangadharam PR. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623.
15. Saito H, Sato K. 1989. Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice. Tubercle 70:201-205.
16. Shafran SD, et al. 1996. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N. Engl. J. Med. 335:377-383.
17. Shen GH, et al. 2010. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int. J. Antimicrob. Agents 35:400-404.
18. Siddiqi SH, et al. 1993. Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J. Clin. Microbiol. 31:2332-2338.
19. van Ingen J, Boeree MJ, Dekhuijzen PNR, van Soolingen D. 2008. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur. Respir. J. 31:106-109.
20. van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL. 2012. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int. J. Antimicrob. Agents. 39:173-176.
21. van Ingen J, Boeree MJ, van Soolingen D, Mouton JW. 2012. Mechanisms of drug resistance and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat. 15:149-161.
22. van Ingen J, et al. 2012. The pharmacokinetics and pharmacodynamics of Mycobacterium avium complex disease treatment. Am. J. Respir. Crit. Care Med. 186:559-565.
23. Winthrop KL, et al. 2010. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am. J. Respir. Crit. Care Med. 182:977-982.